呼吸器合胞体ウイルスワクチンの世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

呼吸器合胞体ウイルスワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7%で18億2,840万米ドルに成長します。この予測期間における成長は、承認済みワクチンの導入、世界の予防接種プログラム、高齢者の増加、ヘルスケアインフラの成長などに起因しています。予測期間における主要動向としては、技術的進歩、デジタルモニタリングツール、個別化ワクチン、混合ワクチンの開発、アジュバントの革新などが挙げられます。

呼吸器感染症の流行増加は、呼吸器合胞体ウイルス（RSV）ワクチン市場の成長を促進すると予想されます。呼吸器感染症は、副鼻腔、咽頭、気道、肺などの呼吸器系を冒すウイルスや細菌を含む様々な病原体によって引き起こされる疾患です。これらの感染症の罹患率上昇の要因としては、大気汚染、気候変動、都市化、高齢化、薬剤耐性病原体の出現などが挙げられます。RSVワクチンは、特に乳幼児や高齢者のような感染しやすい集団におけるRSV関連疾患を予防することで、感染症の発生率を低下させるのに役立ちます。例えば、英国健康安全保障局は2024年10月、イングランドにおける結核患者が2022～2023年にかけて10.7％増加し、4,380人から4,850人に増加したと報告しました。このような呼吸器感染症の罹患率の増加は、RSVワクチン市場の拡大を加速させると予想されます。

RSVワクチン市場の主要動向は、ワクチン技術の進歩、特に組換えタンパク質をベースとした技術の利用に注目が集まっていることです。この技術には、免疫反応を刺激するワクチンを作るためのタンパク質の遺伝子組み換えが含まれます。例えば、2023年5月、英国の製薬会社GlaxoSmithKlineは、60歳以上のRSVによる下気道疾患を予防するために特別に設計された初のRSVワクチンであるArexvyの承認を米国食品医薬品局（FDA）から取得しました。AREXVYは、組換えタンパク質ベースの技術を用いて、ウイルスがヒト細胞に感染するのに重要なRSV融合（F）タンパク質を標的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場：金利、インフレ、地政学的要因、新型コロナとその回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界の呼吸器合胞体ウイルスワクチン：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の呼吸器合胞体ウイルスワクチン市場：成長率分析
• 世界の呼吸器合胞体ウイルスワクチン市場の実績：規模と成長、2019～2024年
• 世界の呼吸器合胞体ウイルスワクチン市場の予測：規模と成長、2024～2029年、2034年
• 世界の呼吸器合胞体ウイルスワクチン：総潜在市場規模（TAM）

第7章 世界の価格分析と予測

第8章 市場セグメンテーション

• 世界の呼吸器合胞体ウイルスワクチン市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ウイルスワクチン
• 細菌ワクチン
• 混合ワクチン
• 世界の呼吸器合胞体ウイルスワクチン市場：臨床適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児
• 高齢者
• 高リスク者
• 世界の呼吸器合胞体ウイルスワクチン市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院やその他の薬局
• 政府サプライヤー

第9章 臨床適応症の世界的疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界の呼吸器合胞体ウイルスワクチン市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の呼吸器合胞体ウイルスワクチン市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• 呼吸器合胞体ウイルスワクチン市場：競合情勢
• 呼吸器合胞体ウイルスワクチン市場：企業プロファイル
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Moderna Inc.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• 呼吸器合胞体ウイルスワクチン市場、2029年：新たな機会を提供する国
• 呼吸器合胞体ウイルスワクチン市場、2029年：新たな機会を提供するセグメント
• 呼吸器合胞体ウイルスワクチン市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

A respiratory syncytial virus (RSV) vaccine is a medical preparation aimed at protecting individuals, especially infants, older adults, and high-risk groups, from severe respiratory infections caused by RSV. It functions by stimulating the immune system to recognize and combat the virus, thus lowering the risk of hospitalization and severe illness.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of RSV vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is specifically designed to prevent infections caused by viruses. It covers various indications, including those for pediatric, geriatric, and high-risk populations, and is distributed through hospitals, pharmacies, and government suppliers.

The respiratory syncytial virus vaccines market research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus vaccines market statistics, including respiratory syncytial virus vaccines industry global market size, regional shares, competitors with a respiratory syncytial virus vaccines market share, detailed respiratory syncytial virus vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus vaccines industry. This respiratory syncytial virus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory syncytial virus vaccine market size is expected to see strong growth in the next few years. It will grow to $1,828.4 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the introduction of approved vaccines, global immunization programs, a rising geriatric population, and a growing healthcare infrastructure. Major trends in the forecast period include technological advancements, digital monitoring tools, personalized vaccines, the development of combination vaccines, and adjuvant innovations.

The increasing prevalence of respiratory infections is expected to drive the growth of the respiratory syncytial virus (RSV) vaccine market. Respiratory infections are diseases caused by various pathogens, including viruses and bacteria, that affect the respiratory system, such as the sinuses, throat, airways, or lungs. Factors contributing to the rising incidence of these infections include air pollution, climate change, urbanization, an aging population, and the emergence of drug-resistant pathogens. The RSV vaccine helps reduce the incidence of infections by preventing RSV-related illnesses, particularly in vulnerable groups such as infants and the elderly. For example, the UK Health Security Agency reported in October 2024 that tuberculosis (TB) cases in England increased by 10.7% from 2022 to 2023, rising from 4,380 to 4,850 cases. This growing incidence of respiratory infections is expected to accelerate the RSV vaccine market's expansion.

A key trend in the RSV vaccine market is the increased focus on advancements in vaccine technology, particularly the use of recombinant protein-based technology. This technology involves the genetic engineering of proteins to create vaccines that stimulate an immune response. For example, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Arexvy, the first RSV vaccine specifically designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy uses recombinant protein-based technology to target the RSV fusion (F) protein, which is critical to the virus's ability to infect human cells.

In February 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for $1.1 billion. This acquisition strengthens AstraZeneca's pipeline of vaccines and immune therapies, with Icosavax's leading candidate, IVX-A12, targeting RSV and human metapneumovirus (hMPV), two key pathogens responsible for severe respiratory infections in high-risk groups such as the elderly and individuals with chronic conditions. Icosavax, a clinical-stage U.S.-based biopharmaceutical company, is actively developing an RSV vaccine with its lead candidate, IVX-A12.

Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, and Moderna Inc.

North America was the largest region in the respiratory syncytial virus vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory syncytial virus vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the respiratory syncytial virus vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory syncytial virus vaccine market consists of sales of protein-based vaccines, mRNA vaccines, monoclonal antibodies, and live-attenuated vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Syncytial Virus Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory syncytial virus vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory syncytial virus vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory syncytial virus vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
• 2) By Clinical Indications: Pediatric Indication; Geriatric Indication; High-Risk Individuals
• 3) By Distribution Channel: Hospital And Others Pharmacies; Government Suppliers
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Moderna Inc.
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Respiratory Syncytial Virus Vaccine Market Characteristics

3. Respiratory Syncytial Virus Vaccine Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Respiratory Syncytial Virus Vaccine Market Trends And Strategies

5. Respiratory Syncytial Virus Vaccine Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Respiratory Syncytial Virus Vaccine Growth Analysis And Strategic Analysis Framework

• 6.1. Global Respiratory Syncytial Virus Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Respiratory Syncytial Virus Vaccine Market Growth Rate Analysis
• 6.4. Global Respiratory Syncytial Virus Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
• 6.5. Global Respiratory Syncytial Virus Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
• 6.6. Global Respiratory Syncytial Virus Vaccine Total Addressable Market (TAM)

7. Global Respiratory Syncytial Virus Vaccine Pricing Analysis & Forecasts

8. Respiratory Syncytial Virus Vaccine Market Segmentation

• 8.1. Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Viral Vaccine
• Bacterial Vaccine
• Combination Vaccine
• 8.2. Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Pediatric Indication
• Geriatric Indication
• High-Risk Individuals
• 8.3. Global Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Hospitals And Other Pharmacies
• Government Suppliers

9. Global Respiratory Syncytial Virus Vaccine Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Respiratory Syncytial Virus Vaccine Market Regional And Country Analysis

• 10.1. Global Respiratory Syncytial Virus Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 10.2. Global Respiratory Syncytial Virus Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Respiratory Syncytial Virus Vaccine Market

• 11.1. Asia-Pacific Respiratory Syncytial Virus Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.3. Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.4. Asia-Pacific Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Respiratory Syncytial Virus Vaccine Market

• 12.1. China Respiratory Syncytial Virus Vaccine Market Overview
• 12.2. China Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.3. China Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.4. China Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Respiratory Syncytial Virus Vaccine Market

• 13.1. India Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.2. India Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.3. India Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Respiratory Syncytial Virus Vaccine Market

• 14.1. Japan Respiratory Syncytial Virus Vaccine Market Overview
• 14.2. Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.3. Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.4. Japan Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Respiratory Syncytial Virus Vaccine Market

• 15.1. Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.2. Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.3. Australia Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Respiratory Syncytial Virus Vaccine Market

• 16.1. South Korea Respiratory Syncytial Virus Vaccine Market Overview
• 16.2. South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.3. South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.4. South Korea Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Respiratory Syncytial Virus Vaccine Market

• 17.1. Western Europe Respiratory Syncytial Virus Vaccine Market Overview
• 17.2. Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.3. Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.4. Western Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Respiratory Syncytial Virus Vaccine Market

• 18.1. UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.2. UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.3. UK Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Respiratory Syncytial Virus Vaccine Market

• 19.1. Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.2. Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.3. Germany Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Respiratory Syncytial Virus Vaccine Market

• 20.1. France Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.2. France Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.3. France Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Respiratory Syncytial Virus Vaccine Market

• 21.1. Eastern Europe Respiratory Syncytial Virus Vaccine Market Overview
• 21.2. Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.3. Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.4. Eastern Europe Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Respiratory Syncytial Virus Vaccine Market

• 22.1. North America Respiratory Syncytial Virus Vaccine Market Overview
• 22.2. North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.3. North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.4. North America Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Respiratory Syncytial Virus Vaccine Market

• 23.1. USA Respiratory Syncytial Virus Vaccine Market Overview
• 23.2. USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.3. USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.4. USA Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Respiratory Syncytial Virus Vaccine Market

• 24.1. Canada Respiratory Syncytial Virus Vaccine Market Overview
• 24.2. Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.3. Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.4. Canada Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Respiratory Syncytial Virus Vaccine Market

• 25.1. South America Respiratory Syncytial Virus Vaccine Market Overview
• 25.2. South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.3. South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.4. South America Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Respiratory Syncytial Virus Vaccine Market

• 26.1. Middle East Respiratory Syncytial Virus Vaccine Market Overview
• 26.2. Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.3. Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.4. Middle East Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Respiratory Syncytial Virus Vaccine Market

• 27.1. Africa Respiratory Syncytial Virus Vaccine Market Overview
• 27.2. Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.3. Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Clinical Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.4. Africa Respiratory Syncytial Virus Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Respiratory Syncytial Virus Vaccine Market Competitive Landscape And Company Profiles

• 28.1. Respiratory Syncytial Virus Vaccine Market Competitive Landscape
• 28.2. Respiratory Syncytial Virus Vaccine Market Company Profiles
  • 28.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Respiratory Syncytial Virus Vaccine Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Respiratory Syncytial Virus Vaccine Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Respiratory Syncytial Virus Vaccine Market

32. Recent Developments In The Respiratory Syncytial Virus Vaccine Market

33. Respiratory Syncytial Virus Vaccine Market High Potential Countries, Segments and Strategies

• 33.1 Respiratory Syncytial Virus Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Respiratory Syncytial Virus Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Respiratory Syncytial Virus Vaccine Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer